{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:43:08Z","timestamp":1785148988128,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peroxiredoxin 2 (PRDX2) is an antioxidant and molecular chaperone that can be secreted from tumor cells. But the role of PRDX2 in acute myocardial infarction (AMI) is not clear. In the current study, we demonstrate the role of PRDX2 from clinical trials, H9c2 cells and in a mouse model. ELISA analysis shows that serum concentrations of VEGF and inflammatory factor IL-1\u03b2, TNF-\u03b1 and IL-6 were increased in AMI patients compared to a control group. The expression of PRDX2 was also upregulated. <jats:italic>In vivo<\/jats:italic> experiments show that the expression of PRDX2 inhibits hypoxia-induced oxidative stress injury to H9c2 cells. However, PRDX2 expression promotes TLR4 mediated inflammatory factor expression and VEGF expression under hypoxia conditions. PRDX2 overexpression in H9c2 cells also promotes human endothelial cell migration, vasculogenic mimicry formation and myocardial hypertrophy related protein expression. The overexpression of PRDX2 inhibits ROS level and myocardial injury after AMI but promotes inflammatory responses <jats:italic>in vivo<\/jats:italic>. Immunocytochemistry and immunofluorescence analysis show that overexpression of PRDX2 promotes angiogenesis and myocardial hypertrophy. Taken together, our results indicate that PRDX2 plays two roles in acute infarction \u2013 the promotion of cell survival and inflammatory myocardial hypertrophy.<\/jats:p>","DOI":"10.1038\/s41598-017-06718-7","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T13:11:34Z","timestamp":1501074694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["PRDX2 in Myocyte Hypertrophy and Survival is Mediated by TLR4 in Acute Infarcted Myocardium"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5535-0460","authenticated-orcid":false,"given":"Xian","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5442-2271","authenticated-orcid":false,"given":"Yanwen","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"key":"6718_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.018","volume":"163","author":"MH Park","year":"2016","unstructured":"Park, M. H., Jo, M., Kim, Y. R., Lee, C. K. & Hong, J. T. Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases. Pharmacol Ther \n                           163, 1\u201323 (2016).","journal-title":"Pharmacol Ther"},{"key":"6718_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.14348\/molcells.2016.2349","volume":"39","author":"LE Netto","year":"2016","unstructured":"Netto, L. E. & Antunes, F. The Roles of Peroxiredoxin and Thioredoxin in Hydrogen Peroxide Sensing and in Signal Transduction. Mol Cells \n                           39, 65\u201371 (2016).","journal-title":"Mol Cells"},{"key":"6718_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.freeradbiomed.2013.04.032","volume":"61","author":"M Jo","year":"2013","unstructured":"Jo, M. et al. Lung tumor growth-promoting function of peroxiredoxin 6. Free Radic Biol Med \n                           61, 453\u2013463 (2013).","journal-title":"Free Radic Biol Med"},{"key":"6718_CR4","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1158\/0008-5472.CAN-10-3674","volume":"71","author":"JR Riddell","year":"2011","unstructured":"Riddell, J. R. et al. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res \n                           71, 1637\u20131646 (2011).","journal-title":"Cancer Res"},{"key":"6718_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/jcb.24412","volume":"114","author":"A Cimini","year":"2013","unstructured":"Cimini, A. et al. Neuroprotective effects of PrxI over-expression in an in vitro human Alzheimer\u2019s disease model. J Cell Biochem \n                           114, 708\u2013715 (2013).","journal-title":"J Cell Biochem"},{"key":"6718_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0304-3835(00)00434-1","volume":"156","author":"T Yanagawa","year":"2000","unstructured":"Yanagawa, T. et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett \n                           156, 27\u201335 (2000).","journal-title":"Cancer Lett"},{"key":"6718_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0968-0004(02)00003-8","volume":"28","author":"ZA Wood","year":"2003","unstructured":"Wood, Z. A., Schroder, E., Robin Harris, J. & Poole, L. B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci \n                           28, 32\u201340 (2003).","journal-title":"Trends Biochem Sci"},{"key":"6718_CR8","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1182\/blood-2002-08-2548","volume":"101","author":"TH Lee","year":"2003","unstructured":"Lee, T. H. et al. Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood \n                           101, 5033\u20135038 (2003).","journal-title":"Blood"},{"key":"6718_CR9","doi-asserted-by":"publisher","first-page":"30615","DOI":"10.1074\/jbc.272.49.30615","volume":"272","author":"P Zhang","year":"1997","unstructured":"Zhang, P. et al. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem \n                           272, 30615\u201330618 (1997).","journal-title":"J Biol Chem"},{"key":"6718_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00395-008-0764-6","volume":"104","author":"W Zhao","year":"2009","unstructured":"Zhao, W. et al. Protection of peroxiredoxin II on oxidative stress-induced cardiomyocyte death and apoptosis. Basic Res Cardiol \n                           104, 377\u2013389 (2009).","journal-title":"Basic Res Cardiol"},{"key":"6718_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1172\/JCI6709","volume":"104","author":"S Frantz","year":"1999","unstructured":"Frantz, S. et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest \n                           104, 271\u2013280 (1999).","journal-title":"J Clin Invest"},{"key":"6718_CR12","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/nm.2749","volume":"18","author":"T Shichita","year":"2012","unstructured":"Shichita, T. et al. Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med \n                           18, 911\u2013917 (2012).","journal-title":"Nat Med"},{"key":"6718_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.14348\/molcells.2016.2341","volume":"39","author":"B Knoops","year":"2016","unstructured":"Knoops, B., Argyropoulou, V., Becker, S., Ferte, L. & Kuznetsova, O. Multiple Roles of Peroxiredoxins in Inflammation. Mol Cells \n                           39, 60\u201364 (2016).","journal-title":"Mol Cells"},{"key":"6718_CR14","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/eci.12118","volume":"43","author":"P Christia","year":"2013","unstructured":"Christia, P. & Frangogiannis, N. G. Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest \n                           43, 986\u2013995 (2013).","journal-title":"Eur J Clin Invest"},{"key":"6718_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tox.2013.08.009","volume":"312","author":"XS Dong","year":"2013","unstructured":"Dong, X. S. et al. Toll-like receptor 4 is involved in myocardial damage following paraquat poisoning in mice. Toxicology \n                           312, 115\u2013122 (2013).","journal-title":"Toxicology"},{"key":"6718_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cardiores.2005.05.025","volume":"68","author":"T Ha","year":"2005","unstructured":"Ha, T. et al. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res \n                           68, 224\u2013234 (2005).","journal-title":"Cardiovasc Res"},{"key":"6718_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cyto.2014.08.005","volume":"71","author":"TD Crafts","year":"2015","unstructured":"Crafts, T. D., Jensen, A. R., Blocher-Smith, E. C. & Markel, T. A. Vascular endothelial growth factor: therapeutic possibilities and challenges for the treatment of ischemia. Cytokine \n                           71, 385\u2013393 (2015).","journal-title":"Cytokine"},{"key":"6718_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s11481-014-9531-7","volume":"9","author":"S Ramakrishnan","year":"2014","unstructured":"Ramakrishnan, S., Anand, V. & Roy, S. Vascular endothelial growth factor signaling in hypoxia and inflammation. J Neuroimmune Pharmacol \n                           9, 142\u2013160 (2014).","journal-title":"J Neuroimmune Pharmacol"},{"key":"6718_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jb\/mvs136","volume":"153","author":"M Shibuya","year":"2013","unstructured":"Shibuya, M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem \n                           153, 13\u201319 (2013).","journal-title":"J Biochem"},{"key":"6718_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.molcel.2011.08.040","volume":"44","author":"DH Kang","year":"2011","unstructured":"Kang, D. H. et al. Peroxiredoxin II is an essential antioxidant enzyme that prevents the oxidative inactivation of VEGF receptor-2 in vascular endothelial cells. Mol Cell \n                           44, 545\u2013558 (2011).","journal-title":"Mol Cell"},{"key":"6718_CR21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","volume":"19","author":"K Holmes","year":"2007","unstructured":"Holmes, K., Roberts, O. L., Thomas, A. M. & Cross, M. J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal \n                           19, 2003\u20132012 (2007).","journal-title":"Cell Signal"},{"key":"6718_CR22","first-page":"697","volume":"7","author":"T Zhao","year":"2015","unstructured":"Zhao, T. et al. VEGF-C\/VEGFR-3 pathway promotes myocyte hypertrophy and survival in the infarcted myocardium. Am J Transl Res \n                           7, 697\u2013709 (2015).","journal-title":"Am J Transl Res"},{"key":"6718_CR23","first-page":"305","volume":"12","author":"L Fang","year":"2015","unstructured":"Fang, L., Moore, X. L., Dart, A. M. & Wang, L. M. Systemic inflammatory response following acute myocardial infarction. J Geriatr Cardiol \n                           12, 305\u2013312 (2015).","journal-title":"J Geriatr Cardiol"},{"key":"6718_CR24","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.lfs.2013.03.014","volume":"92","author":"GD Duerr","year":"2013","unstructured":"Duerr, G. D. et al. Myocardial hypertrophy is associated with inflammation and activation of endocannabinoid system in patients with aortic valve stenosis. Life Sci \n                           92, 976\u2013983 (2013).","journal-title":"Life Sci"},{"key":"6718_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/FJC.0000000000000003","volume":"63","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis, N. G. The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J Cardiovasc Pharmacol \n                           63, 185\u2013195 (2014).","journal-title":"J Cardiovasc Pharmacol"},{"key":"6718_CR26","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1253\/circj.CJ-15-0440","volume":"79","author":"K Hao","year":"2015","unstructured":"Hao, K. et al. Clinical Characteristics of Patients With Acute Myocardial Infarction Who Did Not Undergo Primary Percutaneous Coronary Intervention- Report From the MIYAGI-AMI Registry Study. Circ J \n                           79, 2009\u20132016 (2015).","journal-title":"Circ J"},{"key":"6718_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.109.880187","volume":"121","author":"F Arslan","year":"2010","unstructured":"Arslan, F. et al. Myocardial ischemia\/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation \n                           121, 80\u201390 (2010).","journal-title":"Circulation"},{"key":"6718_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/CIRCRESAHA.107.158220","volume":"102","author":"L Timmers","year":"2008","unstructured":"Timmers, L. et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res \n                           102, 257\u2013264 (2008).","journal-title":"Circ Res"},{"key":"6718_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1472-6793-7-5","volume":"7","author":"SC Kim","year":"2007","unstructured":"Kim, S. C. et al. Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function. BMC Physiol \n                           7, 5 (2007).","journal-title":"BMC Physiol"},{"key":"6718_CR30","doi-asserted-by":"publisher","first-page":"12157","DOI":"10.1073\/pnas.1401712111","volume":"111","author":"S Salzano","year":"2014","unstructured":"Salzano, S. et al. Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proc Natl Acad Sci USA \n                           111, 12157\u201312162 (2014).","journal-title":"Proc Natl Acad Sci USA"},{"key":"6718_CR31","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.cardiores.2004.07.017","volume":"64","author":"M Ikeuchi","year":"2004","unstructured":"Ikeuchi, M. et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res \n                           64, 526\u2013535 (2004).","journal-title":"Cardiovasc Res"},{"key":"6718_CR32","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1160\/TH07-01-0022","volume":"97","author":"NG Frangogiannis","year":"2007","unstructured":"Frangogiannis, N. G. Chemokines in ischemia and reperfusion. Thromb Haemost \n                           97, 738\u2013747 (2007).","journal-title":"Thromb Haemost"},{"key":"6718_CR33","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1161\/01.RES.0000130526.20854.fa","volume":"94","author":"M Nian","year":"2004","unstructured":"Nian, M., Lee, P., Khaper, N. & Liu, P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res \n                           94, 1543\u20131553 (2004).","journal-title":"Circ Res"},{"key":"6718_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2174\/1568010033484098","volume":"2","author":"G Ren","year":"2003","unstructured":"Ren, G., Dewald, O. & Frangogiannis, N. G. Inflammatory mechanisms in myocardial infarction. Curr Drug Targets Inflamm Allergy \n                           2, 242\u2013256 (2003).","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"6718_CR35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1172\/JCI113364","volume":"81","author":"PJ Simpson","year":"1988","unstructured":"Simpson, P. J. et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest \n                           81, 624\u2013629 (1988).","journal-title":"J Clin Invest"},{"key":"6718_CR36","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1161\/01.CIR.0000112575.66565.84","volume":"109","author":"J Oyama","year":"2004","unstructured":"Oyama, J. et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation \n                           109, 784\u2013789 (2004).","journal-title":"Circulation"},{"key":"6718_CR37","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3892\/mmr.2014.2316","volume":"10","author":"J Feng","year":"2014","unstructured":"Feng, J. et al. Overexpression of peroxiredoxin 2 inhibits TGF-beta1-induced epithelial-mesenchymal transition and cell migration in colorectal cancer. Mol Med Rep \n                           10, 867\u2013873 (2014).","journal-title":"Mol Med Rep"},{"key":"6718_CR38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/onc.2012.93","volume":"32","author":"V Stresing","year":"2013","unstructured":"Stresing, V. et al. Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene \n                           32, 724\u2013735 (2013).","journal-title":"Oncogene"},{"key":"6718_CR39","doi-asserted-by":"publisher","first-page":"e50394","DOI":"10.1371\/journal.pone.0050394","volume":"7","author":"JR Riddell","year":"2012","unstructured":"Riddell, J. R. et al. Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1alpha. PLoS One \n                           7, e50394 (2012).","journal-title":"PLoS One"},{"key":"6718_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.intimp.2016.10.025","volume":"41","author":"DL Liu","year":"2016","unstructured":"Liu, D. L., Zhao, L. X., Zhang, S. & Du, J. R. Peroxiredoxin 1-mediated activation of TLR4\/NF-kappaB pathway contributes to neuroinflammatory injury in intracerebral hemorrhage. Int Immunopharmacol \n                           41, 82\u201389 (2016).","journal-title":"Int Immunopharmacol"},{"key":"6718_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1471-2202-11-125","volume":"11","author":"R Tulsawani","year":"2010","unstructured":"Tulsawani, R. et al. Neuroprotective effect of peroxiredoxin 6 against hypoxia-induced retinal ganglion cell damage. BMC Neurosci \n                           11, 125 (2010).","journal-title":"BMC Neurosci"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-06718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-06718-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-06718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T07:44:11Z","timestamp":1671781451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-06718-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["6718"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-06718-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,1]]},"assertion":[{"value":"8 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6970"}}